Nymox Enlarged Prostate Drug Fails To Meet Primary Endpoints In Phase 3 Studies

(RTTNews) - Nymox Pharmaceutical Corp. (NYMX) announced that its two Phase 3 U.S. studies of NX-1207 for the treatment of enlarged prostate or benign prostatic hyperplasia or BPH, NX02-0017 and NX02-0018, failed to meet their primary efficacy endpoints. Full results will be reported at a later date.

The company noted that the two studies failed to meet the pre-specified efficacy endpoints. Drug safety was acceptable. Drug efficacy reached levels similar to earlier studies but was not statistically significant in comparison to the placebo control due to a higher placebo response than in earlier NX-1207 studies and in other placebo-controlled BPH studies.

The compound remains promising for low grade localized prostate cancer where the Phase 2 results showed evidence that NX-1207 treatment had a positive effect on biopsy results and clinical and biochemical progression.